We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+12.11%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$177M
AUM Growth
+$177M
Cap. Flow
+$20.1M
Cap. Flow %
11.35%
Top 10 Hldgs %
37.39%
Holding
117
New
21
Increased
27
Reduced
33
Closed
35

Top Buys

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$3.68M
2
FULC icon
Fulcrum Therapeutics
FULC
+$3.52M
3
CERS icon
Cerus
CERS
+$3.5M
4
ARVN icon
Arvinas
ARVN
+$3.29M
5
NXTC icon
NextCure
NXTC
+$3.18M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$5.49M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$2.79M
3
MSAC
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
+$2.54M
4
RNLX
Renalytix plc American Depositary Shares
RNLX
+$2.3M
5
CRIS icon
Curis
CRIS
+$1.54M

Sector Composition

Rank Sector Weight
1 Healthcare 89.56%
2 Financials 5.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCUS icon
101
PUT
Arcus Biosciences
RCUS
$3.55B
– –
-60,400
Closed -$1.66K
RLMD icon
102
Relmada Therapeutics
RLMD
$562M
– –
-46,729
Closed -$1.5K
SAGE
103
CALL
DELISTED
Sage Therapeutics
SAGE
– –
-9,300
Closed -$528
DCOY
104
Decoy Therapeutics
DCOY
$2.09M
– –
-13
Closed -$500
SNDX icon
105
Syndax Pharmaceuticals
SNDX
$1.73B
– –
-34,727
Closed -$596
VSTM icon
106
Verastem
VSTM
$536M
– –
-87,446
Closed -$4.27K
WVE icon
107
Wave Life Sciences
WVE
$1.11B
– –
-123,972
Closed -$826
XBI icon
108
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-94,400
Closed -$12.8K
CERE
109
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-15,000
Closed -$1.66K
MDNA
110
DELISTED
Medicenna Therapeutics Corp. Common Shares
MDNA
– –
-110,515
Closed -$333
RETA
111
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-9,346
Closed -$1.32K
KDNY
112
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-14,158
Closed -$12.8K
TCRR
113
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-188,142
Closed -$3.09K
FMTX
114
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
– –
-9,679
Closed -$241
ODT
115
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
– –
-186,680
Closed -$652
TRIL
116
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-95,190
Closed -$923
CHAQ.WS
117
DELISTED
Chardan Healthcare Acquisition 2 Corp. Warrants, entitling the holder thereof to purchase one-half (
CHAQ.WS
– –
-104,828
Closed -$85
1 2 3 4
5

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Silverarc Capital Management held 117 positions worth $177M, up 78,789% from $224K the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Silverarc Capital Management deployed $20.1M of net new capital in Q3 2021, opening 21 new positions and adding to 27 existing holdings. Its largest new stake was Fulcrum Therapeutics: 185,691 shares worth $5.24M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 79% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Dicerna Pharmaceuticals, Inc., an estimated $5.49M trimmed.

  • Silverarc Capital Management's largest Q3 2021 buy was Fulcrum Therapeutics: 185,691 shares worth $5.24M.
  • Silverarc Capital Management added most to Cogent Biosciences in Q3 2021, an estimated $3.68M increase.
  • Silverarc Capital Management's biggest Q3 2021 reduction was Dicerna Pharmaceuticals, Inc., cutting an estimated $5.49M.
  • Silverarc Capital Management fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2021, selling an estimated $12.8K.
  • Silverarc Capital Management's ten largest holdings make up 37% of its $177M portfolio in Q3 2021.
  • Silverarc Capital Management opened 21 new positions and closed 35 in Q3 2021.
  • Silverarc Capital Management's portfolio value rose 78,789% quarter-over-quarter to $177M.

Based on Silverarc Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.